West Pharmaceutical Services (WST) Cash & Equivalents (2009 - 2026)

West Pharmaceutical Services' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $521.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 29.0% year-over-year to $521.4 million; the TTM figure through Mar 2026 stood at $521.4 million (up 29.0% YoY), while the FY2025 annual figure was $791.3 million, up 63.29% from the prior year.
• Cash & Equivalents came in at $521.4 million for Q1 2026 at West Pharmaceutical Services, down from $791.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $898.6 million in Q3 2023 to a low of $404.2 million in Q1 2025.
• A 5-year average of $666.1 million and a median of $667.7 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 45.37% in 2024 and surged 63.29% in 2025, its largest moves.
• West Pharmaceutical Services' Cash & Equivalents stood at $894.3 million in 2022, then retreated by 4.52% to $853.9 million in 2023, then sank by 43.25% to $484.6 million in 2024, then soared by 63.29% to $791.3 million in 2025, then sank by 34.11% to $521.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $521.4 million, $791.3 million, and $628.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison